No active 13F manager changed its position in OACCU last quarter. No recent Form 4 insider filings for OACCU.
No leg leans either way.
4 tracked 13F filers disclose a position in OACCU as of the latest SEC 13F filings, a combined $8.5M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Shares | Position value | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | ADAR1 Capital Management, LLC | 516K | $5.5M | —Held | Q1 2026 | |
| 2 | Affinity Asset Advisors, LLC | 250K | $2.7M | —Held | Q1 2026 | |
| 3 | Clear Street Group Inc. | 22K | $242K | ▼−1.1% Reduced · −246 sh | Q2 2026 | |
| 4 | UBS Group AG | 10K | $104K | —Held | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| Company | Co-held by | Their position there |
|---|---|---|
| Abivax Sa-ADRABVX | 2 funds | $200.3M |
| Roivant Sciences LtdROIV | 2 funds | $168.6M |
| Protagonist Therapeutics IncPTGX | 2 funds | $122.9M |
| Xenon Pharmaceuticals IncXENE | 2 funds | $110.7M |
| Cytokinetics IncCYTK | 2 funds | $87.9M |
| Erasca IncERAS | 2 funds | $86.7M |
| Insmed IncINSM | 2 funds | $84.3M |
| Spyre Therapeutics IncSYRE | 2 funds | $81.6M |
| Terns Pharmaceuticals Inc430 | 2 funds | $77.9M |
| Immunovant IncIMVT | 2 funds | $69.0M |
| Centessa Pharmaceuticals-ADRCNTA | 2 funds | $57.1M |
| Praxis Precision Medicines IPRAX | 2 funds | $55.3M |
Ranked by how many of OACCU's tracked holders also hold each name. The last column is those co-holders' combined reported position in that name, not in OACCU.
No open-market insider transactions on file yet. Grants, gifts, and exercises live on the full insider page.
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 0 | 1 | – |
Insiders Form 4 open-market | 0 | 0 | $0 |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
| Class | 13F holders | Value held |
|---|---|---|
| OACCSHSCL | 49 funds | $189.0M |
| OACCWWarrant | 29 funds | $2.4M |
| OACCUthis pageUNIT 10/04/2029 | 4 funds | $8.5M |
Same issuer, multiple share classes. The consensus leaderboards count this company once across all classes; this is the per-class detail.
No filings captured for this ticker in the live stream yet.
Connected entities for OACCU
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/OACCU/capital-change-brief"
Use Arkolith's capital_change_brief for OACCU. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + the live filing stream, joined for OACCU. Filings are public domain, sourced to SEC EDGAR.